$5.66
Today
as of Jul 22, 16:55 ET
Last 30 days
Recent Press Releases & News
Taysha Gene Therapies (TSHA) is One of The Most Affordable Biotech Names to Invest In
Taysha Gene Therapies Insider Sold Shares Worth $1,248,000, According to a Recent SEC Filing
Taysha's R&D Chief Sold $1.2 Million in Stock After a 149% Run
Overview
52-week range
$2.25
$7.30
68% of range
Avg surprise (last 3)
-16.2%
Avg reaction (last 2)
+4.3%
100% positive
Latest IV / EM
112%
EM ±25.6% · $6 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Wed May 6, 2026 | Mar/2026 | $-0.12 | $-0.10 | -20.0% | -50.0% | +0.6% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.09 | — | — | — | — | financials |
| Tue Aug 12, 2025 | Jun/2025 | $-0.09 | $-0.07 | -28.6% | — | — | earnings |
| Thu May 15, 2025 | Mar/2025 | $-0.08 | $-0.08 | 0.0% | — | +8.0% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.10 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.09 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.10 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.93 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.38 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Aug 11, 2026 | Jun/2026 | OTHER | -$0.11 | -$0.09 | -22.2% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | — | $0 | $2M | $2M | — | $2M | $1M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-43M | — | $-34M | $-27M | $-21M | — | $-26M | $-21M |
| Net income | $-42M | — | $-33M | $-27M | $-22M | — | $-26M | $-21M |
| EPS (diluted) | $-0.12 | — | $-0.09 | $-0.09 | $-0.08 | — | $-0.10 | $-0.09 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $277M | $320M | $297M | $313M | $117M | $139M | $158M | $173M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $282M | $325M | $300M | $316M | $121M | $142M | $162M | $178M |
| Total assets | $300M | $343M | $317M | $333M | $138M | $160M | $180M | $200M |
| Long-term debt | $49M | $50M | $51M | $41M | $42M | $44M | $43M | $38M |
| Total liabilities | $88M | $96M | $98M | $85M | $83M | $89M | $91M | $92M |
| Total equity | $212M | $247M | $219M | $249M | $55M | $72M | $89M | $109M |